CGI-S is measured on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill patients)
Food and Drug Administration (2025) Tirzepatide, StatPearls [Internet] (2024) Adverse events related to tirzepatide, Journal of the Endocrine Society (2023) Tirzepatide-induced gastrointestinal manifestations: A systematic review and meta-analysis, Cureus (2023) Gastrointestinal adverse events of tirzepatide in the treatment of Type 2 diabetes mellitus: A meta-analysis and trials sequential analysis, Medicine (2023) Glucagon-like peptide-1 receptor agonists, StatPearls [Internet] (2024) How may GIP enhance the therapeutic efficacy of GLP-1?, Trends in Endocrinology & Metabolism (2020) Comparative efficacy of tirzepatide vs
Synergistic Research Applications MOTS-c is frequently researched alongside complementary mitochondrial, metabolic, neuroregulatory, and recovery-focused compounds due to its role in metabolic signaling and mitochondrial-adaptation pathways
Medical guidelines recommend a gradual 48 week taper instead
Your prescriber will monitor glucose levels and adjust therapy accordingly
The triple interactions between gut microbiota, mycobiota and host immunity